Literature DB >> 18795974

Anti-inflammatory effects of tumour necrosis factor (TNF)-alpha are mediated via TNF-R2 (p75) in tolerogenic transforming growth factor-beta-treated antigen-presenting cells.

Sharmila Masli1, Bruce Turpie.   

Abstract

Exposure of macrophages to transforming growth factor (TGF)-beta is known to alter their functional phenotype such that antigen presentation by these cells leads to tolerance rather than an inflammatory immune response. Typically, eye-derived antigen-presenting cells (APCs) exposed to TGF-beta in the local environment are known to induce a form of peripheral tolerance and protect the eye from inflammatory immune effector-mediated damage. In response to TGF-beta, APCs increase their expression of tumour necrosis factor (TNF)-alpha and TNF receptor 2 (TNF-R2). Although TNF-alpha has been implicated in tolerance and the associated regulation of the inflammatory immune response, its source and the receptors involved remain unclear. In this report we determined the contribution of TNF-alpha and TNF-R2 expressed by TGF-beta-treated APCs to their anti-inflammatory tolerogenic effect. Our results indicate that APC-derived TNF-alpha is essential for the ability of APCs to regulate the immune response and their IL-12 secretion. Moreover, in the absence of TNF-R2, APCs exposed to TGF-beta failed to induce tolerance or regulatory cells known to participate in this tolerance. Also, blocking of TNF-R1 signalling enhanced the ability of the APCs to secrete increased TGF-beta in response to TGF-beta exposure. Together our results support an anti-inflammatory role of TNF-alpha in regulation of an immune response by TGF-beta-treated APCs and suggest that TNF-R2 contributes significantly to this role.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18795974      PMCID: PMC2678182          DOI: 10.1111/j.1365-2567.2008.02933.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  46 in total

1.  Analysis of an in vitro-generated signal that induces systemic immune deviation similar to that elicited by antigen injected into the anterior chamber of the eye.

Authors:  Y Hara; R R Caspi; B Wiggert; M Dorf; J W Streilein
Journal:  J Immunol       Date:  1992-09-01       Impact factor: 5.422

2.  A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease.

Authors:  S E Plevy; C J Landers; J Prehn; N M Carramanzana; R L Deem; D Shealy; S R Targan
Journal:  J Immunol       Date:  1997-12-15       Impact factor: 5.422

3.  TGF-beta promotes immune deviation by altering accessory signals of antigen-presenting cells.

Authors:  M Takeuchi; P Alard; J W Streilein
Journal:  J Immunol       Date:  1998-02-15       Impact factor: 5.422

4.  Expression of thrombospondin in TGFbeta-treated APCs and its relevance to their immune deviation-promoting properties.

Authors:  Sharmila Masli; Bruce Turpie; Karl H Hecker; J Wayne Streilein
Journal:  J Immunol       Date:  2002-03-01       Impact factor: 5.422

5.  Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept?

Authors:  Stefan Ehlers
Journal:  Clin Infect Dis       Date:  2005-08-01       Impact factor: 9.079

6.  IL-12 as mediator and adjuvant for the induction of contact sensitivity in vivo.

Authors:  G Müller; J Saloga; T Germann; G Schuler; J Knop; A H Enk
Journal:  J Immunol       Date:  1995-11-15       Impact factor: 5.422

7.  Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumor necrosis factor receptor.

Authors:  L A Tartaglia; D V Goeddel; C Reynolds; I S Figari; R F Weber; B M Fendly; M A Palladino
Journal:  J Immunol       Date:  1993-11-01       Impact factor: 5.422

8.  Inhibition of interferon gamma induced interleukin 12 production: a potential mechanism for the anti-inflammatory activities of tumor necrosis factor.

Authors:  J Hodge-Dufour; M W Marino; M R Horton; A Jungbluth; M D Burdick; R M Strieter; P W Noble; C A Hunter; E Puré
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

9.  Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series.

Authors:  Stephen J Jarrett; Gaye Cunnane; Philip G Conaghan; Sarah J Bingham; Maya H Buch; Mark A Quinn; Paul Emery
Journal:  J Rheumatol       Date:  2003-10       Impact factor: 4.666

10.  Role of interleukin 12 and costimulators in T cell anergy in vivo.

Authors:  L Van Parijs; V L Perez; A Biuckians; R G Maki; C A London; A K Abbas
Journal:  J Exp Med       Date:  1997-10-06       Impact factor: 14.307

View more
  23 in total

1.  The tumor necrosis factor receptor stalk regions define responsiveness to soluble versus membrane-bound ligand.

Authors:  Christine Richter; Sylvia Messerschmidt; Gerlinde Holeiter; Jessica Tepperink; Sylvia Osswald; Andrea Zappe; Marcus Branschädel; Verena Boschert; Derek A Mann; Peter Scheurich; Anja Krippner-Heidenreich
Journal:  Mol Cell Biol       Date:  2012-04-30       Impact factor: 4.272

2.  Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model.

Authors:  Philana Ling Lin; Amy Myers; Le'Kneitah Smith; Carolyn Bigbee; Matthew Bigbee; Carl Fuhrman; Heather Grieser; Ion Chiosea; Nikolai N Voitenek; Saverio V Capuano; Edwin Klein; JoAnne L Flynn
Journal:  Arthritis Rheum       Date:  2010-02

3.  Inflammatory 'double hit' model of temporomandibular joint disorder with elevated CCL2, CXCL9, CXCL10, RANTES and behavioural hypersensitivity in TNFR1/R2-/- mice.

Authors:  S L McIlwrath; R Nesemeier; F Ma; H S Oz; L Zhang; K N Westlund
Journal:  Eur J Pain       Date:  2017-03-20       Impact factor: 3.931

4.  Therapeutic window for cyclooxygenase-2 related anti-inflammatory therapy after status epilepticus.

Authors:  Jianxiong Jiang; Myung-Soon Yang; Yi Quan; Paoula Gueorguieva; Thota Ganesh; Raymond Dingledine
Journal:  Neurobiol Dis       Date:  2015-01-17       Impact factor: 5.996

5.  Direct bone formation during distraction osteogenesis does not require TNFalpha receptors and elevated serum TNFalpha fails to inhibit bone formation in TNFR1 deficient mice.

Authors:  Elizabeth C Wahl; James Aronson; Lichu Liu; Robert A Skinner; Mike J Miller; Gael E Cockrell; John L Fowlkes; Kathryn M Thrailkill; Robert C Bunn; Martin J J Ronis; Charles K Lumpkin
Journal:  Bone       Date:  2009-09-17       Impact factor: 4.398

Review 6.  Functional plasticity of macrophages: in situ reprogramming of tumor-associated macrophages.

Authors:  Robert D Stout; Stephanie K Watkins; Jill Suttles
Journal:  J Leukoc Biol       Date:  2009-07-15       Impact factor: 4.962

7.  Mesenchymal stem cells inhibit cutaneous radiation-induced fibrosis by suppressing chronic inflammation.

Authors:  Jason A Horton; Kathryn E Hudak; Eun Joo Chung; Ayla O White; Bradley T Scroggins; Jeffrey F Burkeen; Deborah E Citrin
Journal:  Stem Cells       Date:  2013-10       Impact factor: 6.277

8.  Dendritic cell maturation and survival are differentially regulated by TNFR1 and TNFR2.

Authors:  Anja Krippner-Heidenreich; Catharien M U Hilkens; Nicola J Maney; Gary Reynolds
Journal:  J Immunol       Date:  2014-10-06       Impact factor: 5.422

9.  An intracameral injection of antigen induces in situ chemokines and cytokines required for the generation of circulating immunoregulatory monocytes.

Authors:  Roshan Pais; Sourojit Bhowmick; Subhasis Chattopadhyay; Yen Lemire; Roshanak Sharafieh; Rajwahrdan Yadav; James O'Rourke; Robert E Cone
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

10.  Local expression of tumor necrosis factor-receptor 1:immunoglobulin G can induce salivary gland dysfunction in a murine model of Sjögren's syndrome.

Authors:  Jelle L Vosters; Hongen Yin; Nienke Roescher; Marc R Kok; Paul P Tak; John A Chiorini
Journal:  Arthritis Res Ther       Date:  2009-12-14       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.